文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重症监护病房脓毒症成人静脉注射维生素C

Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.
PubMed 文献 · N Engl J Med · 2022-06-15
一句话结论在ICU接受血管升压药治疗的脓毒症成人中,静脉注射维生素C组28天死亡或持续器官功能障碍风险高于安慰剂组(RR 1.21)。

该随机安慰剂对照试验纳入ICU入住不超过24小时、以确诊或疑似感染为主要诊断且正在使用血管升压药的成人,比较维生素C(50 mg/kg,每6小时一次,最多96小时)与匹配安慰剂的疗效。主要终点为28天死亡或持续器官功能障碍的复合终点,维生素C组发生率为44.5%(191/429),对照组为38.5%(167/434),风险比1.21(95%CI 1.04-1.40,P=0.01)。28天死亡、持续器官功能障碍、器官功能障碍评分、生物标志物、6个月生存等两组相似。结论提示此类患者静脉注射维生素C的28天死亡或持续器官功能障碍风险高于安慰剂。

要点

  • ICU脓毒症使用血管升压药的成人中,维生素C组28天死亡或持续器官功能障碍44.5%(191/429)vs 安慰剂组38.5%(167/434),RR 1.21(95%CI 1.04-1.40,P=0.01)。
  • 28天死亡:维生素C组35.4%(152/429)vs 安慰剂组31.6%(137/434),RR 1.17(95%CI 0.98-1.40)。
  • 28天持续器官功能障碍:维生素C组9.1%(39/429)vs 安慰剂组6.9%(30/434),RR 1.30(95%CI 0.83-2.05)。
  • 器官功能障碍评分、生物标志物、6个月生存、健康相关生活质量、3期急性肾损伤及低血糖事件两组相似。
  • 维生素C组报告1例严重低血糖事件和1例严重过敏反应事件。

适用人群与场景

  • 成人,ICU入住时间不超过24小时,以确诊或疑似感染为主要诊断,且正在接受血管升压药治疗。

处置流程与药物剂量

  • 维生素C组:维生素C按50 mg/kg剂量静脉输注,每6小时一次,最多96小时。
  • 对照组:匹配安慰剂,给药方案与维生素C组相同。

红旗征与不能漏的情况

  • 维生素C组报告1例严重低血糖事件。
  • 维生素C组报告1例严重过敏反应事件。

研究设计与关键结果

  • 随机、安慰剂对照试验,872例患者随机分组(维生素C组435例,对照组437例)。
  • 主要终点(28天死亡或持续器官功能障碍复合终点):维生素C组191/429(44.5%)vs 对照组167/434(38.5%),RR 1.21(95%CI 1.04-1.40,P=0.01)。
  • 28天死亡:维生素C组152/429(35.4%)vs 安慰剂组137/434(31.6%),RR 1.17(95%CI 0.98-1.40)。
  • 28天持续器官功能障碍:维生素C组39/429(9.1%)vs 安慰剂组30/434(6.9%),RR 1.30(95%CI 0.83-2.05)。
  • 器官功能障碍评分、生物标志物、6个月生存、健康相关生活质量、3期急性肾损伤及低血糖事件两组相似。
  • 不良事件:维生素C组1例严重低血糖事件,1例严重过敏反应事件。

证据类型、等级与局限

  • 研究类型:随机、安慰剂对照试验。
  • 资助:Lotte and John Hecht Memorial Foundation;LOVIT试验,ClinicalTrials.gov注册号NCT03680274。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU接受血管升压药治疗的脓毒症成人中,静脉注射维生素C(50 mg/kg每6小时一次,最多96小时)组28天死亡或持续器官功能障碍风险高于安慰剂组(RR 1.21,95%CI 1.04-1.40,P=0.01),原文结论提示该人群使用静脉维生素C的该风险高于安慰剂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Studies that have evaluated the use of intravenous vitamin C in adults with sepsis who were receiving vasopressor therapy in the intensive care unit (ICU) have shown mixed results with respect to the risk of death and organ dysfunction.

METHODS: In this randomized, placebo-controlled trial, we assigned adults who had been in the ICU for no longer than 24 hours, who had proven or suspected infection as the main diagnosis, and who were receiving a vasopressor to receive an infusion of either vitamin C (at a dose of 50 mg per kilogram of body weight) or matched placebo administered every 6 hours for up to 96 hours. The primary outcome was a composite of death or persistent organ dysfunction (defined by the use of vasopressors, invasive mechanical ventilation, or new renal-replacement therapy) on day 28.

RESULTS: A total of 872 patients underwent randomization (435 to the vitamin C group and 437 to the control group). The primary outcome occurred in 191 of 429 patients (44.5%) in the vitamin C group and in 167 of 434 patients (38.5%) in the control group (risk ratio, 1.21; 95% confidence interval [CI], 1.04 to 1.40; P = 0.01). At 28 days, death had occurred in 152 of 429 patients (35.4%) in the vitamin C group and in 137 of 434 patients (31.6%) in the placebo group (risk ratio, 1.17; 95% CI, 0.98 to 1.40) and persistent organ dysfunction in 39 of 429 patients (9.1%) and 30 of 434 patients (6.9%), respectively (risk ratio, 1.30; 95% CI, 0.83 to 2.05). Findings were similar in the two groups regarding organ-dysfunction scores, biomarkers, 6-month survival, health-related quality of life, stage 3 acute kidney injury, and hypoglycemic episodes. In the vitamin C group, one patient had a severe hypoglycemic episode and another had a serious anaphylaxis event.

CONCLUSIONS: In adults with sepsis receiving vasopressor therapy in the ICU, those who received intravenous vitamin C had a higher risk of death or persistent organ dysfunction at 28 days than those who received placebo. (Funded by the Lotte and John Hecht Memorial Foundation; LOVIT ClinicalTrials.gov number, NCT03680274.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lamontagne F, Masse MH, Menard J, et al. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. N Engl J Med. 2022. PMID: 35704292. doi:10.1056/NEJMoa2200644

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。